Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large.
Experts Share Insights & Advice on Reproductive Health for Patients with Rheumatic Disease
Contraception, disease control, family planning and managing life with an infant—five experts addressed these concerns and more for patients with rheumatic disease during a special online webinar.
Vasculitis Guidelines in Focus, Part 4: Polyarteritis Nodosa
Jason Springer, MD, MS, served as one of the lead authors of the ACR/VF guidelines for polyarteritis nodosa (PAN), and talks about the recommendations specific to PAN here.
Rheumatologists Saw a Gain in Compensation in 2020
Although patient volume temporarily declined due to the COVID-19 pandemic, rheumatologists saw a larger increase in compensation in 2020 than in 2019, according to a recent Medscape survey.
Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease
Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.
Oral CBD Fails to Relieve Pain from Hand OA & PsA
NEW YORK (Reuters Health)—Lower doses of cannabidiol (CBD) failed to provide any meaningful reduction in pain when added to other analgesic therapy in patients with hand osteoarthritis (OA) or psoriatic arthritis (PsA) in a randomized, placebo-controlled study from Denmark.1 Writing in the journal, Pain, Jonathan Vela, MD, and colleagues of Aalborg University note that CBD…
Inspired by Healthcare Disparities to Advocate for Change
Seeing the challenges her rural patients faced in accessing specialty care, Amanda Schnell, MD, was inspired to make advocacy an integral part of her work at the University of Alabama at Birmingham.
RheumPAC Advocacy Fund: Effecting Change
Professional practices, state societies and other organizations can support RheumPAC’s work with corporate funds through the RheumPAC Advocacy Fund.
FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%
The FDA has granted a seven-year marketing exclusivity for Octagam 10%, a 10% solution of a human intravenous immunoglobulin (IVIG) that treats adults with dermatomyositis.
Rituximab for Children with Lupus Nephritis
NEW YORK (Reuters Health)—Pediatric rheumatologists and nephrologists appear to differ in their treatment choices for children who have lupus nephritis (LN), with rheumatologists more likely to prescribe rituximab, results of a small survey suggest. “This study highlights the importance of collaborative effort in developing CTPs (Consensus Treatment Plans) for pediatric LN,” the authors write in…
- « Previous Page
- 1
- …
- 129
- 130
- 131
- 132
- 133
- …
- 814
- Next Page »